Dexcom G6 Continuous Glucose Monitoring in Hemodialysis

Comparison of Dexcom G6 Continuous Glucose Monitoring System and Blood Glucose Levels in Adult Hemodialysis Patients With Diabetes

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04217161

Acronym

DEXCOM-HD

Enrollment

Registered

2020-01-03

Start date

2020-03-01

Completion date

2023-12-21

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Glucose Measurement, Hemodialysis

Brief summary

This is a pilot study enrolling adult hemodialysis patients with diabetes recruited from the University of California Irvine Medical Center (UCIMC) who will undergo simultaneous measurement of glucose levels using 1) continuous glucose monitor (CGM) measured by a Dexcom G6 device vs. 2) gold-standard blood glucose levels using capillary fingerstick or venous blood glucose measurements obtained on a point of care (POC) blood glucose meter. The study will assess Dexcom G6 accuracy by comparing glucose levels on the CGM device vs. blood glucose measurements in the study population.

Interventions

DEVICEDexcom G6 Continuous Glucose Monitor

Eligible patients will undergo DDexcom G6 Continuous Glucose Monitor device placement

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult hemodialysis patients age 18 years or older * Have a comorbidity of diabetes * Receipt of care from the inpatient University of California Irvine Medical Center nephrology consult service * Expected hospital stay ≥48 hours * Have the ability to directly provide informed consent for participation in the study

Exclusion criteria

* Critically-ill patients receiving care in the intensive care unit (ICU) or cardiac care unit (CCU) * Moribund patients expected to die within 48 hours * Presence of any condition deemed by PI's judgment that would seriously limit life expectancy (i.e., poor survival) * Pregnant * Unwilling or unable to provide informed consent

Design outcomes

Primary

Measure	Time frame	Description
Blood glucose measurement	3 to 5 days	Proportion of CGM values within 20% of blood glucose levels \>100 mg/dl or within 20 mg/dl of blood glucose level for levels \<=100 mg/dl. (Will examine different thresholds of CGM values within a certain range of blood glucose levels, i.e., 10%, 15%, 25%.)

Secondary

Measure	Time frame	Description
Hypoglycemia events	3 to 5 days	Comparison in number of hypoglycemia events (glucose \<70 mg/dl) determined by CGM or by blood glucose measurements

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026